Evidence map›Paper›PMID 34781748›Full record

ArticlemBio2021

Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.

Paula Ruiz-Rodriguez, Clara Francés-Gómez, Álvaro Chiner-Oms, Mariana G López, Santiago Jiménez-Serrano, Irving Cancino-Muñoz, Paula Ruiz-Hueso, Manuela Torres-Puente, Maria Alma Bracho, Giuseppe D'Auria and 11 more

Abstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Antigens from the HelminthInternational journal of molecular sciences · 2023
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Paula Ruiz-Rodriguez *I2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.ORCID 0000-0003-0727-5974
Clara Francés-Gómez *I2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.ORCID 0000-0001-7341-3824
Álvaro Chiner-OmsInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.
Mariana G LópezInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.
Santiago Jiménez-SerranoInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.
Irving Cancino-MuñozInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.
Paula Ruiz-HuesoSequencing and Bioinformatics Service of Valencian Region Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain.
Manuela Torres-PuenteInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.
Maria Alma BrachoI2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
Giuseppe D'AuriaI2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
Llúcia Martinez-PriegoSequencing and Bioinformatics Service of Valencian Region Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain.
Manuel GuerreiroHematology Department, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
Marta Montero-AlonsoInfectious Diseases Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain.
María Dolores GómezMicrobiology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
José Luis PiñanaHematology Service, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain.
SeqCOVID-SPAIN Consortium
Fernando González-CandelasI2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.
Iñaki ComasInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.ORCID 0000-0001-5504-9408
Alberto MarinaInstituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain.ORCID 0000-0002-1334-5273
Ron GellerI2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.ORCID 0000-0002-7612-4611
Mireia CoscollaI2SysBio, University of Valenciagrid.5338.d-CSIC, FISABIO Joint Research Unit Infection and Public Health, Valencia, Spain.ORCID 0000-0003-0752-0538

Funding

European Commission-NextGenerationEUGVA | Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana (CIUCSD) SEJI/2019/011MEC | Consejo Superior de Investigaciones Científicas (CSIC) CSIC-COV19-021MEC | Instituto de Salud Carlos III (ISCIII) COV20/00140Ministerio de Ciencia, Innovación y Universidades (MCIU) RTI2018-094399-A-I00
6 · The paper itself

Abstract

We have detected two mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at amino acid positions 1163 and 1167 that appeared independently in multiple transmission clusters and different genetic backgrounds. Furthermore, both mutations appeared together in a cluster of 1,627 sequences belonging to clade 20E. This cluster is characterized by 12 additional single nucleotide polymorphisms but no deletions. The available structural information on the S protein in the pre- and postfusion conformations predicts that both mutations confer rigidity, which could potentially decrease viral fitness. Accordingly, we observed reduced infectivity of this spike genotype relative to the ancestral 20E sequence

Indexed as

Evolution, MolecularMutationPhenotypeAntibodies, NeutralizingCOVID-19EuropeGenetic VariationGenome, ViralHumansNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2adaptive mutationsantibody escapehomoplasyHR2SARS-CoV-2spikevariants

Identifiers

PMID34781748
PMCPMC8593680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.